Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00237250 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 171
- Enrollment target
NCT00237250: Completed Phase 3 study, sponsored by Novartis.
NCT00237250 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 171 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00237250, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 171 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to placebo in lowering post-meal blood glucose levels in people with pre-diabetes who have high blood sugar levels after meals.
Interventions
- DRUG vildagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2005-10 |
| Est. Completion | 2006-07 |
| Phase | Phase 3 |
What the finished NCT00237250 record still lists
NCT00237250 is an interventional study that assigns participants to a tested intervention. The registered 171 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 1 intervention - of which vildagliptin is the first listed.
NCT00237250 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00237250 about?
NCT00237250 is a clinical study titled "Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance". The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to placebo in lowering post-meal blood glucose levels in people with pre-diabetes who have high blood sugar levels after meals.
What is the current status of trial NCT00237250?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 171 participants. The study started on 2005-10. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00237250?
The interventions under investigation include: vildagliptin (DRUG).
Who is sponsoring clinical trial NCT00237250?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00237250's enrollment target sits among peer trials
171 1451st of 2000 higher than 548 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02641145 · 171 participants · NA
Molecular Imaging of Primary Amyloid Cardiomyopathy
- NCT05541029 · 171 participants · NA
Music Listening: A Mechanistic Trial
- NCT05561127 · 171 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel
- NCT05592938 · 171 participants · NA
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia